Bruker Corporation

NasdaqGS:BRKR 株式レポート

時価総額：US$9.1b

Bruker 配当と自社株買い

配当金 基準チェック /06

Bruker配当を支払う会社であり、現在の利回りは0.34%です。

主要情報

0.3%

配当利回り

-0.09%

バイバック利回り

総株主利回り0.3%
将来の配当利回り0.3%
配当成長5.2%
次回配当支払日n/a
配当落ち日n/a
一株当たり配当金n/a
配当性向-83%

最近の配当と自社株買いの更新

Recent updates

ナラティブ更新 • Jul 10

BRKR: Diagnostics Portfolio Momentum Will Counter Valuation And Execution Uncertainty

The analyst fair value estimate for Bruker has been raised from $53.25 to $56.00 after analysts responded to a series of higher Street price targets and updated models across diagnostics and life sciences tools coverage. Analyst Commentary Recent Street research on Bruker shows a mix of optimism and caution, with several firms updating price targets and ratings as they refresh models across diagnostics and life sciences tools coverage.
ナラティブ更新 • Jun 26

BRKR: Rich Multiple And Execution Risks Will Pressure Earnings Power Into 2026

Bruker’s analyst fair value estimate has been revised from $36.80 to $35.00 as analysts weigh a richer valuation, even as several recent price target increases in the $60 to $65 range cite updated models and improving sentiment toward life science and diagnostic tools stocks. Analyst Commentary Recent Street commentary on Bruker shows a clear divide between optimistic targets and more cautious views that question how much upside is left at current prices.
ナラティブ更新 • Jun 11

BRKR: Semiconductor And Diagnostics Momentum Will Balance Helium And Execution Risks

The updated analyst price target for Bruker has moved from an implied fair value of $49.15 to $53.25, reflecting recent target hikes into the $65 range by several firms as analysts incorporate refreshed models, sector sentiment, and valuation concerns into their views. Analyst Commentary Recent research updates show a mix of optimism and caution around Bruker, with price targets clustering around US$65 alongside more neutral stances that focus on valuation and operating risks.
ナラティブ更新 • May 28

BRKR: Rising Helium Costs Will Constrain Earnings Power Into 2026

Analysts have lifted their average price target on Bruker by about $1.80, citing updated assumptions that include a slightly lower discount rate, modestly higher revenue growth and profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism on long term prospects and concern about near term risks.
ナラティブ更新 • May 14

BRKR: 2026 Earnings Delivery Will Outweigh Helium Cost Headwinds

Bruker's updated analyst price target has shifted to $49.15 from $47.86, as analysts factor in moderate adjustments to discount rates, revenue growth, profit margins and expected future P/E multiples, following a mix of recent target raises and cuts across the Street. Analyst Commentary Recent research on Bruker reflects a split view, with some analysts lifting price targets and others trimming them, as they reassess valuation, execution risk and potential headwinds in key input costs.
ナラティブ更新 • Apr 29

BRKR: Helium Cost Pressures And Margin Execution Will Shape 2026 Path

Analysts have trimmed their average price targets on Bruker by several dollars to reflect helium cost headwinds, recent margin pressure and lower valuation multiples, while underlying long term revenue growth and profit margin assumptions remain broadly consistent. Analyst Commentary Bearish analysts have been resetting expectations on Bruker, with several firms cutting price targets by mid single digit to low double digit dollar amounts.
ナラティブ更新 • Apr 15

BRKR: Rising Helium Costs Will Pressure Margins And Test 2026 Earnings

Analysts have reduced their Bruker price targets by mid single digit dollar amounts, citing lower margin expectations, helium related cost headwinds and revised sector multiples. These factors, in turn, feed into a higher implied future P/E and modest adjustments to growth and discount rate assumptions.
ナラティブ更新 • Apr 01

BRKR: 2026 Earnings Framework And Helium Risk Will Shape Future P/E

Bruker's updated analyst price target edges lower to about $48 per share, as analysts trim fair value and future P/E assumptions while factoring in helium cost risks and recent price target resets across the coverage group. Analyst Commentary Recent Street research on Bruker reflects a mix of optimism around long term growth targets and caution around nearer term execution, margins, and input cost risks.
Seeking Alpha • Mar 31

Bruker: A Better, Yet Speculative Proposition

Summary Bruker's shares have declined 40% since January, pressured by weak 2025 results and a cautious 2026 outlook. 2025 saw organic sales decline 4%, high leverage (~3x), and significant M&A activity, raising concerns about capital allocation. 2026 guidance calls for modest 4–5% sales growth, 1–2% organic, and adjusted EPS of $2.10–$2.15, lowering valuation to 15–16x earnings. While conviction remains low due to uneven execution, the risk-reward is improving, warranting consideration of a small speculative position on further dips. Read the full article on Seeking Alpha
ナラティブ更新 • Mar 18

BRKR: 2026 Earnings Framework And Spatial Biology Expansion Will Support Higher P/E

Analysts have reduced the average Bruker price target to about $48, citing helium cost headwinds, a Q4 margin miss and lower sector valuation multiples, while noting that longer term earnings expectations remain in place. Analyst Commentary Research commentary on Bruker highlights a mix of optimism on long term earnings power and caution around near term execution risks and input costs, particularly helium.
ナラティブ更新 • Mar 03

BRKR: Reset Margins And 2026 Outlook Will Support Higher Forward P/E

Analysts have reset their view on Bruker, trimming the target to about $48 from about $54 as they factor in recent Q4 margin pressure, higher assumed discount rates and lower profit margin expectations. This comes even as revenue growth forecasts and future P/E assumptions move higher and Street research shows a mix of price target cuts and raises across firms.
ナラティブ更新 • Feb 17

BRKR: Future Earnings Reset Will Test 2026 Margin Ramp Assumptions

Analysts have trimmed their fair value estimate for Bruker to $35 from $38, reflecting lower applied multiples on future earnings targets after recent price target cuts across several firms, even as updated assumptions factor in changes to revenue growth and profit margins. Analyst Commentary Recent Street research around Bruker has turned more mixed, with several bearish analysts cutting price targets after the latest quarterly update, even as some firms maintain positive ratings or modestly higher targets.
分析記事 • Feb 15

Analysts Have Been Trimming Their Bruker Corporation (NASDAQ:BRKR) Price Target After Its Latest Report

It's been a sad week for Bruker Corporation ( NASDAQ:BRKR ), who've watched their investment drop 13% to US$36.51 in...
ナラティブ更新 • Feb 03

BRKR: Q4 Setup And BEST Agreements Will Support Higher Forward P/E Multiple

Analysts have lifted their price targets on Bruker by amounts such as $5, $13 and to $53, citing updated views on the life science tools sector and Q4 setups. This feeds into our slightly higher fair value estimate and revised assumptions for discount rate, revenue growth, profit margin and future P/E.
ナラティブ更新 • Jan 20

BRKR: Constructive Bookings And Rating Upgrade Will Support Higher Forward P E Multiple

Analysts have lifted their Bruker price target to about $54 from about $52, citing slightly higher fair value estimates and modest adjustments to the discount rate, margin assumptions, and future P/E expectations. These changes are supported by a series of recent target hikes and an upgrade to Hold in the life science tools peer group.
ナラティブ更新 • Jan 06

BRKR: Constructive Bookings And Rating Upgrade Will Shape Balanced Forward Expectations

Analysts have raised their price target on Bruker by about US$0.57 to around US$52.36, reflecting updated views that factor in steadier bookings and the recent shift from Sell to Hold in Street ratings. Analyst Commentary Recent Street research on Bruker reflects a more balanced stance, with some analysts turning less negative while still highlighting execution risks and guidance concerns.
ナラティブ更新 • Dec 17

BRKR: Constructive Bookings And Rating Upgrade Will Support Stronger Forward Expectations

Analysts have modestly raised their price target on Bruker to about $52 from roughly $49, citing constructive bookings trends that help offset the impact of a 2025 guidance cut and support a slightly higher long term growth and valuation outlook. Analyst Commentary Analyst reactions to Bruker reflect a balanced mix of optimism and caution, with modest target price increases and a shift in ratings signaling improving sentiment but also recognition of execution and guidance risks.
ナラティブ更新 • Dec 03

BRKR: Constructive Bookings And Rating Upgrades Will Support Stable Forward Expectations

Analysts have modestly increased their price target on Bruker to approximately $49 from about $48, citing constructive bookings despite 2025 guidance cuts and recent upgrades in rating outlook. Analyst Commentary Analyst reactions to Bruker’s updated outlook highlight a more balanced risk and reward profile, with some modest upward revisions to valuation targets despite tempered near term expectations.
分析記事 • Nov 26

Bruker Corporation's (NASDAQ:BRKR) Shares Bounce 26% But Its Business Still Trails The Industry

Bruker Corporation ( NASDAQ:BRKR ) shares have continued their recent momentum with a 26% gain in the last month alone...
ナラティブ更新 • Nov 19

BRKR: Booking Momentum Will Improve Sentiment Despite Lowered 2025 Outlook

Analysts have modestly increased their price target for Bruker from $40 to $43, citing more constructive bookings and improved financial metrics, even though 2025 guidance has been lowered. Analyst Commentary Recent analyst updates reflect a complex view of Bruker's prospects, with nuanced shifts in expectations tied to the company's latest financial disclosures and forward guidance.
ナラティブ更新 • Nov 03

BRKR: Recent Upgrade Will Drive Confidence In Core Market Resilience

Narrative Update: Bruker Analyst Price Target Increased Analysts have raised Bruker's fair value price target by approximately $1.09 to $47.82, citing improved ratings and updated market assessments, even as growth expectations have moderated slightly. Analyst Commentary Bullish Takeaways Bullish analysts note that the recent price target increase reflects greater confidence in Bruker’s ability to deliver stable financial results in the near term.
分析記事 • Aug 10

Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge

NasdaqGS:BRKR 1 Year Share Price vs Fair Value Explore Bruker's Fair Values from the Community and select yours The...
ナラティブ更新 • Aug 06

Renewed Biopharma Funding And Cost Savings Will Revitalize Markets

Bruker's consensus analyst price target has declined notably, primarily due to weaker revenue growth forecasts and a lower forward P/E multiple, resulting in a reduced fair value estimate of $46.73. What's in the News Bruker provided guidance for FY2025, projecting revenues of $3.43-$3.50 billion (2%-4% reported growth), driven mainly by M&A (3.5%) and FX tailwind (2.5%), but expects 2%-4% organic revenue decline; Q2 2025 revenue is projected to be approximately flat year-over-year at $795-$798 million (Key Developments).

決済の安定と成長

配当データの取得

安定した配当: BRKRはUS市場で注目すべき配当金を支払っていないため、支払いが安定しているかどうかを確認する必要はありません。

増加する配当: BRKRはUS市場で注目すべき配当金を支払っていないため、支払額が増加しているかどうかを確認する必要はありません。

配当利回り対市場

Bruker 配当利回り対市場
BRKR 配当利回りは市場と比べてどうか？
セグメント配当利回り
会社 (BRKR)0.3%
市場下位25% (US)1.4%
市場トップ25% (US)4.2%
業界平均 (Life Sciences)0.6%
アナリスト予想 (BRKR) (最長3年)0.3%

注目すべき配当: BRKRの配当金 ( 0.34% ) はUS市場の配当金支払者の下位 25% ( 1.36% ) と比べると目立ったものではありません。

高配当: BRKRの配当金 ( 0.34% ) はUS市場の配当金支払者の上位 25% ( 4.16% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: BRKR US市場において目立った配当金を支払っていません。

株主配当金

キャッシュフローカバレッジ: BRKR US市場において目立った配当金を支払っていません。

高配当企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/13 18:56
終値2026/07/13 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bruker Corporation 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29

アナリスト機関
Luke SergottBarclays
Michael RyskinBofA Global Research
Paul KnightBrean Capital Historical (Janney Montgomery)